“showed a trend”

In contrast, the PMCA1b mRNA showed a trend to increase with age in jejunum ( P = 0.0059) and ileum ( P = 0.0825) whereas there was a decrease for PMCA1b protein in 12-18 wk ( P ≤ 0.0009).

rs588765 and rs16969968 showed a trend for the PANAS Nervous at 4 mg (p = 0.006 and 0.007 respectively).

LIC showed a trend similar to that of serum ferritin—we observed a significant decrease over time, considering the whole group and the patients with good compliance ( p = 0.006) but not those with poor compliance (0.7).

CTBP2(1) and CTBP2(4) transcripts showed a trend towards lower expression in prostate cancer subjects treated with hormone therapy ( CTBP2(1) ; (0.87 [0.40] in untreated subjects versus 0.31[IQR0.17]; p = 0.006) and CTBP2(4) transcripts (1.01[IQR 0.99] in untreated subjects versus 0.45 [IQR0.42] in treated subjects; p = 0.006) but these results do not reach statistical significance following adjustment for multiple testing (P = < 0.004 for 12 independent tests).

Among S group patients, the patients with R0 resection showed a trend of longer PFS compared with the patients with R2 resection (median PFS 33 vs. 12months, p = 0.006).

While human PCa FMT1 and FMT6 showed a trend to increase (734 ± 30% and 63 ± 22%, respectively) TRAMP-C2 tumour mass compared to autologous mouse FMT, FMT2, 3, 4 and 5 all led to bigger tumours (127 ± 4% p = 0.006, two-sided t -test, 199 ± 13% p = 0.007, two-sided t -test, 247 ± 26% p = 0.04, two-sided t -test and 166 ± 15% p = 0.01, two-sided t-test, respectively) in the recipient animals (Fig. 3c ).

A retrospective study testing the efficacy of corticosteroids as adjuvant therapy to surgery (142 patients with adjuvant corticosteroids and 56 patients without adjuvant corticosteroids) showed a trend toward a survival benefit with medical treatment (risk of death three-fold less in the case of adjuvant corticosteroids ( p = 0.006)) [ 24 ].

The increase after the DER-diet showed a trend towards higher levels compared to the relative change in the restricted diet ( p = 0.006) and the control group ( p = 0.003) ( Table 2 ).

Renal function-related indices also demonstrated significant associations, with serum creatinine levels decreasing significantly ( p < 0.001) with increasing α-klotho levels, from 82.20 ± 55.43 umol/L in Q1 to 68.35 ± 25.71 umol/L in Q4; similarly, uric acid levels showed a significant decreasing trend ( p < 0.001) from 336.06 in Q1 ± 85.56 umol/L to 289.05 ± 82.82 umol/L in Q4.Blood urea nitrogen likewise showed a trend of negative correlation ( p = 0.006) with α-klotho level from 5.13 ± 2.33 mmol/L in Q1 to 4.57 ± 1.67 mmol/L in Q4.

The ccRCC patients with mutated BAP1 showed a trend towards higher AJCC stage ( P =0.006), pathologic T stage ( P =0.009), Fuhrman grade ( P =0.003) and distant metastasis ( P =0.029) compared with those with wild-type BAP1 ( Table 1 ).

Patients performed significantly worse than controls and relatives in the Random condition (Tukey’s HSD, p values < 0.01, Cohen’s d = 1.12), significantly worse than relatives in the Orthogonal condition (Tukey’s HSD, p = 0.041, Cohen’s d = 0.68), and showed a trend toward poorer Orthogonal performance versus controls that did not survive correction for multiple comparisons (uncorrected p = 0.006, Cohen’s d = 0.50).

The rs714939 SNP was also the only marker that showed a trend for association with PIQ (P = 0.006).

Adding interaction terms for interferon plus lopinavir/ritonavir, interferon plus ribavirin, and lopinavir/ritonavir plus ribavirin in the Cox‐PH regression analysis showed a trend toward synergy between interferons and ribavirin in the full dataset (AHR = 6.04, P = 0.006; Figure 3 ), as well as in the additional analysis taking in quality assessments to account for potential bias: respiratory data limited to drug quality and in data limited to only viral load quality 1 data ( Figure S4 , Figure S5 ).

Nevertheless, pooling of data from the rs2296147 polymorphism showed a trend toward an increase in survival of disease with HR of 0.42 (TT vs CC: 95% CI = 0.23–0.78, P heterogeneity = 0.708, I 2 = 0.0%, P = 0.006; Figure 3 ).

Statin-treated patients showed a trend to a more stable plaque morphology, a significantly decreased number of fascin+ and CD83+ DCs (2.1-fold decrease, P = 0.006; 3.6-fold decrease, P = 0.04), and a significantly higher emergence of FoxP3+ Tregs (2.6-fold increase, P = 0.04) ( Figure 6 ).

Bacterial metabolites of the quinolinine pathway may interfere with the outcome of infection When assessing virulence of each strain through survival of mice during acute lung infection, we showed a trend toward decreased survival in mice infected with CHA∆kynU strain compared to those infected with CHA∆kynA strain ( p = 0063) (Fig. 7 ).

The small cohort of patients showed a trend of increased prevalence of S. aureus colonization in HIV positive patients ( p = 0065).

After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSS MAX : −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief.

Patients with MAPT mutations showed a trend towards more severe atrophy in left entorhinal cortex (U = 2.0, z = −2.68, p = .007) and fusiform gyrus (U = 1.5, z = −2.72, p = .006) and right perirhinal cortex (U = 1.5, z = −2.67, p = .007) than patients with mutations in the GRN and C9orf72 gene and in right fusiform gyrus compared to bvFTD patients with no gene mutation (U = 13.0, z = −2.80, p = .005). 4 Discussion In this large cohort of bvFTD patients naming problems were a prominent feature of many, although not all, patients (around 50%).

The SNP rs3779381 was a proxy for the SNP rs3801387 on the WNT16 gene in the GEFOS dataset and showed a trend towards an association with the FN and LS BMD ( P = 0.007 and 0.005, resp.), which was above the multiple test significance threshold that was estimated at 0.001 (0.05/43).

Shammas Cooke showed a trend toward lower MAE in LenStar (p = 0.007), whereas the Haigis-L performance was comparable between devices (p = 0.715) ( Figure 1 ).

In a planned interim report of the FOxTROT phase III trial presented at ASCO 2020, investigating the efficacy and safety of neoadjuvant chemotherapy in 1053 T3-4, N0-2 colon cancer patients, relapse or persistent disease after two years showed a trend toward improvement at 15.6% for neoadjuvant chemotherapy vs. 19.5% for adjuvant chemotherapy ( p = 0.007) [ 43 ].

Patients without pathologically involved lymph nodes showed a trend towards survival benefits compared with patients with regional lymph nodes (HR =2.509, 95% CI: 1.285–4.898; P=0.007) or distant lymph nodes (HR =4.247, 95% CI: 1.399–12.895; P=0.011).

Under a strict Bonferroni correction criteria (α = 0.005), analysis of the combined dataset showed a trend for positive association for WNT3 (rs9890413) in individuals with deep caries and AP, both under allelic and dominant genotype models (P = 0.007).

Patients developing grade II hepatotoxicity showed a trend towards a shorter survival (median OS, 7 months (95% CI, 6–8) versus 14 (95% CI, 11–17), p = 0.007, Figure 4 B).